Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Cardiometabolic Candidate Endotypes in Psoriatic Disease: Integration of Clinical, Metabolic, and Immunogenetic Data
Rubén Queiro1,2,3, Paula Alvarez1, Ignacio Braña1
1Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.
Insights
Integrating the HLA-Cw6 gene marker into analyses of psoriatic disease (PsD) identified distinct cardiometabolic phenotypes. The study found opposite associations of HLA-Cw6 with high-risk profiles in psoriasis versus psoriatic arthritis, suggesting disease-specific implications.
Area of Science:
- Immunogenetics
- Cardiology
- Rheumatology
Background:
- Psoriatic disease (PsD), encompassing psoriasis (PsO) and psoriatic arthritis (PsA), presents heterogeneous cardiometabolic risks.
- Integrating immunogenetic markers like HLA-Cw6 may refine PsD phenotyping and identify distinct endotypes.
Purpose of the Study:
- To identify cardiometabolic phenotypes across PsD by integrating HLA-Cw6 data.
- To explore disease-specific heterogeneity and predictors of high-risk profiles within PsD.
Main Methods:
- A cross-sectional study involved 572 PsD patients, utilizing k-means clustering (k=4) with eight variables including HLA-Cw6.
- Cardiometabolic risk factors were profiled, and cluster validity was assessed using Gaussian Mixture Models and PCA.
- Stratified analyses for PsO and PsA were performed, with logistic regression examining predictors of high-risk phenotypes.
Main Results:
- Four distinct cardiometabolic phenotypes were identified, including a high-risk subgroup (~6%) with older age, cardiovascular disease, hypertension, diabetes, and dyslipidemia.
- High-risk phenotypes were observed in both PsO and PsA patient groups.
- HLA-Cw6 showed opposing associations: enriched in high-risk PsO (OR 2.0) but depleted in high-risk PsA (OR 0.24).
Conclusions:
- Clustering with HLA-Cw6 identified reproducible cardiometabolic phenotypes with unique genetic signatures.
- Inverse HLA-Cw6 risk patterns in PsO and PsA suggest disease-specific cardiometabolic implications.
- Longitudinal studies are warranted to validate these findings and their clinical implications.
Background/Objectives:
Psoriatic disease (PsD) encompasses psoriasis (PsO) and psoriatic arthritis (PsA) and is associated with heterogeneous cardiometabolic risk. Integrating immunogenetic markers such as HLA-Cw6 into data-driven analyses may refine phenotyping and uncover clinically meaningful endotypes. We aimed to identify cardiometabolic phenotypes across PsD, integrating HLA-Cw6 and exploring disease-specific heterogeneity and predictors of high-risk profiles.
Methods:
In a cross-sectional study of 572 PsD patients (401 PsO, 171 PsA), eight demographic and clinical variables, including HLA-Cw6, were entered into k-means clustering (k = 4). Cardiometabolic risk factors were profiled post hoc. Cluster validity was assessed by Gaussian Mixture Models and principal component analysis (PCA). Stratified analyses (k = 3) were conducted separately for PsO and PsA. Predictors of the high-risk phenotype were examined using bootstrap-resampled logistic regression.
Results:
Four cardiometabolic phenotypes were identified, ranging from younger patients with active PsO and low cardiometabolic burden to a small, high-risk subgroup (~6%) combining older age, universal cardiovascular disease, and a clustering of hypertension, diabetes, and dyslipidemia. Disease-stratified analyses showed that high-risk phenotypes were present in both PsO and PsA. In stratified analyses, HLA-Cw6 showed opposite associations-enriched in high-risk PsO (OR 2.0, 95% CI 1.3-3.1) but depleted in high-risk PsA (OR 0.24, 95% CI 0.11-0.52).
Conclusions:
Incorporating HLA-Cw6 into clustering identified reproducible cardiometabolic phenotypes with distinct genetic signatures. The inverse HLA-Cw6 risk patterns in PsO and PsA suggest disease-specific patterns that may have differing cardiometabolic implications, which should be tested in longitudinal studies.
Related Concept Videos
Statistical Software for Data Analysis and Clinical Trials
Chronic Kidney Disease II: Clinical Manifestations
What is Metabolism?
Coronary Artery Disease III: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

